FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN)

Legend Biotech (NASDAQ:LEGN) is one of the 17 biotechnology stocks with more than 50% upside. On January 20, Leonid Timashev of RBC Capital maintained an Outperform rating on Legend Biotech (NASDAQ:LEGN) and set a $66 price target. The analyst shed light on the FDA’s draft guidance that supports the use of Minimal Residual Disease (MRD) negativity and complete response rate to expedite approval endpoints in multiple myeloma. This appears favorable for Legend Biotech (LEGN), as it supports the company’s tr ...